Merck's Keytruda scored two important victories in women's cancer, according to presentations Sunday at the ESMO meeting.

In a historic first, a therapy developed by Summit Therapeutics beat Merck blockbuster Keytruda in late-stage lung cancer ...

Merck’s cancer immunotherapy Keytruda is the drug industry’s biggest blockbuster, bringing in $25 billion in sales last year.

Keytruda's dominance as a mainstay in cancer immunotherapy isn’t threatened by an experimental Chinese drug, a top Merck ...

Merck gets US FDA approval for Keytruda plus pemetrexed & platinum chemotherapy to treat unresectable advanced or metastatic MPM: Rahway, New Jersey Thursday, September 19, 2024, ...

Along with breast cancer, cervical cancer is among the most feared cancer diagnoses for women around the world.

Merck (NYSE:MRK) and Daiichi Sankyo (OTCPK ... (ADC), met the primary endpoint in a Phase 3 trial as a second-line therapy. Citing interim data, the companies said the HERTHENA-Lung02 study ...

The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. | ...

Avelumab is under clinical development by Merck and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II drugs for Cervical Cancer have a 35% phase transition success rate ...

In a report released on September 11, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – ...

Merck’s anti-PD-1 therapy, in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural ...